Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A.
- Sector(s): Healthcare
- Industry: Biotechnology
- Full Time Employees: 62
- Incorporated in 2015
- Headquartered in Cambridge, Massachusetts
- https://sigilon.com
No comments:
Post a Comment